Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nuevolution Appoints Ton Berkien as Chief Business Officer

Published: Tuesday, December 10, 2013
Last Updated: Tuesday, December 10, 2013
Bookmark and Share
Ton Berkien will join the company on January 1, 2014.

Nuevolution A/S has announced that Ton Berkien will join the company on January 1, 2014 as Chief Business Officer.

In his role, Mr. Berkien will lead Nuevolutions commercial and business development efforts and as member of Executive Management, he will play a key part in the strategy planning going forward.

His most recent position was at Takeda/Nycomed, where he was acting Head of Corporate Development/M&A.

In 2012, Nuevolution has announced a new financing round of € 11 Million to catalyze the establishing of an internal pipeline of drug candidates addressing therapeutically important targets within Oncology and Inflammation.

During the last 12 months, Nuevolution has applied its efficient and validated lead discovery technology and has identified small molecule compounds for the first 10 internal target programs and has progressed two of these into lead optimization.

“The appointment of Ton has been made at a strategically important point in time for Nuevolution. During 2014, Nuevolution will be in a position to out-license its first internal programs and further programs will rapidly follow.” said Alex Gouliaev, CEO of Nuevolution A/S. “We are very pleased that Ton has accepted to join us and look forward to benefit from his expertise in the commercialization of Nuevolutions internal programs.”

“I am very pleased to join Nuevolution at such an exciting time for the company. Together with the strong management team, I look forward to contribute to the company’s accelerated growth by driving the commercial efforts forward”, says Ton Berkien.

Most recently, Mr. Berkien served as Senior Director Corporate Development at Takeda Pharmaceuticals International GmbH, Switzerland, where he was responsible for several M&A transactions in the US, and Europe as well as in various Emerging Growth Markets like China, Brazil and Colombia.

Prior to Takeda, he held a similar position at Nycomed Pharmaceuticals. During 2003-2007, Mr. Berkien was Director of Competitive Intelligence at Ferring Pharmaceuticals, where he was responsible CI project management in both the R&D and commercial organization.

Earlier, Mr. Berkien held Senior Manager positions at PricewaterhouseCoopers, Rijnconsult, KPMG and Gilde Investment Management. Mr. Berkien has a BA degree in Economics from the Saxion University of Applied Science in Holland, and an LSid from Harvard Business School/IMD/PwC.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Brian Zambrowicz Joins Nuevolution as Director and Senior Scientific Advisor
Company also announces other Board of Directors.
Thursday, May 22, 2014
Nuevolution Announces Collaboration in Drug Discovery with Boehringer Ingelheim
Partnership to use Nuevolution's Chemetics® technology for lead discovery.
Wednesday, September 21, 2011
Scientific News
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!